BI-HEX®-GlymaxX® cells enable efficient production of next generation biomolecules with enhanced ADCC activity

Abstract

Despite the success story of therapeutic mAbs, a medical need remains to improve lhff effic8cy, for example anbbody dependent ceHular cytotoxiclty (ADCC). Enhanced ADCC Is seen In mAbs with defucosytated gtycans. Experimenbll approach: For produc1ion of ADCC emenced mAbs we have engineered Oii' platform CHO host eel e�exe and generated the novel BMtExe-41ymul(9 host cell. This wn achieved via ProBioGens Glym�chnology by stable nrwfedion with the bacterial RMD enzyme. Stable clones were tasted for stability of RMD exprasslon, as well as glycoprolle 81Juctlae and ADCC ac1ivtty of mAbs produced by theR clones. Results MCI dlsaaslon: BI-HEX9 Glym� eels produce mAbs with a very significant reckJc:ti of fucoae levels . This correlates with strongly enhanced C016 binding and ADCC adivlly. The growth and cutivati properties of 81-HExe-GlymaxX • cell were examined to verify that the engiMered host ceD mainlasled the favourable manufa� properties of BI-HEX9. Depletion stucles confirmed efficient depletion of RMD during downstream purification. In summary, the obtained data lndcate that BI-HEX • ­ GlymaxX • Is a host eel of choice for generation of ADCC­ enhanced therapeu mAbs.